Connect Biopharma Holdings Limited (NASDAQ:CNTB – Get Rating) – Equities researchers at Jefferies Financial Group raised their FY2022 EPS estimates for Connect Biopharma in a research note issued to investors on Tuesday, September 13th. Jefferies Financial Group analyst K. Shi now expects that the company will earn ($1.10) per share for the year, up from their previous estimate of ($2.12). The consensus estimate for Connect Biopharma’s current full-year earnings is ($2.17) per share. Jefferies Financial Group also issued estimates for Connect Biopharma’s FY2023 earnings at ($2.19) EPS, FY2024 earnings at ($1.95) EPS, FY2025 earnings at ($1.74) EPS and FY2026 earnings at ($1.70) EPS.
Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Connect Biopharma in a research report on Thursday, June 2nd.
Connect Biopharma Stock Down 1.4 %
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of CNTB. Ensign Peak Advisors Inc acquired a new position in shares of Connect Biopharma in the fourth quarter worth about $131,000. Deep Track Capital LP acquired a new position in shares of Connect Biopharma during the 4th quarter worth about $3,332,000. Altium Capital Management LP acquired a new position in shares of Connect Biopharma during the 4th quarter worth about $901,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of Connect Biopharma during the 4th quarter worth about $6,438,000. Finally, DLD Asset Management LP acquired a new position in shares of Connect Biopharma during the 4th quarter worth about $627,000. Institutional investors and hedge funds own 27.19% of the company’s stock.
Connect Biopharma Company Profile
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
- Get a free copy of the StockNews.com research report on Connect Biopharma (CNTB)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It’s a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.